Inactivation of GLP-1 leads to glucose intolerance, T2DM and hepatic steatosis (52), suggesting GLP-1 is a potential medication for NAFLD. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.